A Novel Approach To Extend Chemotherapy Efficacy: Sbrt For Oligometastatic Progression.
JOURNAL OF CLINICAL ONCOLOGY(2015)
Abstract
e14569 Background: Stereotactic body radiation therapy ( SBRT) has been used for oligometastatic disease management with local control rates in excess of 90%. Oligoprogression is the term applied to limited disease progression, with overall disease control. Standard care would be changing systemic therapy. A novel approach is to attempt to locally control the progressing lesions and continue the same systemic therapy. For patients on a Tyrosine kinase inhibitor (TKI), progressing lesions were found to accumulate new mutations that cause resistance to the TKI. Hence, treatment with non-overlapping mechanism of resistance such as radiation may be offered. This approach was reported in a retrospective study of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small-cell lung cancer treated with crizotinib, who received SBRT to oligoprogressive disease. This prolonged the duration of therapy with crizotinib as well as overall survival. We hypothesize that progressing lesions in patients u...
MoreTranslated text
Key words
chemotherapy efficacy,oligometastatic progression,sbrt
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined